Functional genomic mRNA (FGmRNA) profiling of > 18,000 tumor samples identifies potential new indications for antibody-drug conjugates (ADCs) in a broad range of tumor types

    Research output: Contribution to journalMeeting AbstractAcademic

    Original languageEnglish
    Number of pages1
    JournalAnnals of Oncology
    Volume28
    Publication statusPublished - Sept-2017
    Event42nd European-Society-for-Medical-Oncology Congress (ESMO) - Madrid, Spain
    Duration: 8-Sept-201712-Sept-2017

    Cite this